TP53 and B-cell chronic lymphocytic leukemia: CLL2-GIVe evaluated the triplet combination IbVenO (IbVenO for 6 cycles, IbVen for further six cycles then MRD-guided duration of Ib monotherapy) for 41 patients with TP53 aberrant CLL; ORR/CR + CRi and PB uMRD rates were 100%/58.5% and 78% respectively, and PFS and OS rates were both 95.1% at 24-month follow-up [111].